Association of lipase lipoprotein polymorphisms with high-density lipoprotein and triglycerides in elderly men by Araujo, Lara Miguel Quirino et al.
©FUNPEC-RP www.funpecrp.com.brGenetics and Molecular Research 9 (1): 89-96 (2010)
Association of lipase lipoprotein polymorphisms 
with high-density lipoprotein and triglycerides 
in elderly men
L.M.Q. Araújo1, M.S. Cendoroglo1, C.O. Gigek2, E.S. Chen2 and
M. de A.C. Smith2
1Disciplina de Geriatria e Gerontologia,
Universidade Federal de São Paulo, São Paulo, SP, Brasil
2Disciplina de Genética, Universidade Federal de São Paulo, São Paulo, SP, Brasil
Corresponding author: L.M.Q. Araújo
E-mail: lara.mqaraujo@gmail.com
Genet. Mol. Res. 9 (1): 89-96 (2010)
Received September 14, 2009
Accepted October 8, 2009
Published January 19, 2010
ABSTRACT. Lipoprotein lipase is essential for triglyceride hydrolysis. 
The polymorphisms S447X in exon 9 and HindIII in intron 8 have been 
associated with lower triglyceride levels and lower cardiovascular risk 
in adult men. We examined the association of these lipoprotein lipase 
polymorphisms with high-density lipoprotein (HDL) and triglyceride levels 
in elderly men. Blood samples were obtained from 87 elderly men, 48 
of whom had cardiovascular disease and 39 (controls) had no history of 
cardiovascular events. The lipoprotein lipase polymorphisms were analyzed 
by PCR-RFLP. Allele frequencies were H- = 27.9% and X = 21.5%. There 
were no significant differences in allele frequencies or blood lipid levels 
between cardiovascular disease and control groups. However, the X allele 
was associated with a lower triglyceride/HDL ratio, 2.30 vs 3.02 for X allele 
absent (P = 0.03); the H-X haplotype was associated with lower triglyceride 
levels compared to the H+S haplotype (1.22 vs 1.58 mM, respectively) and 
a lower triglyceride/HDL ratio (2.29 vs 3.26, respectively). The X allele and 
H-X haplotype were associated with lower triglyceride/HDL ratios in these 
elderly men, independent of the history of cardiovascular events.
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INTRODUCTION
Stroke risk doubles each decade after 55 years of age (Wolf et al., 1992), and the probability 
of coronary artery disease (CAD) in men is also higher with aging (Barreto et al., 2003). There is 
an incidence peak of events in elderly people. Part of these events is explained by lipoprotein me-
tabolism and the relationship between HDL cholesterol and triglyceride-rich lipoproteins (Assmann, 
2004; Windler et al., 2007). Among older patients with myocardial infarction, HDL cholesterol level 
is on average 15 mg/dL lower than in controls (Assmann and Gotto Jr., 2004), and the higher ratio 
of triglycerides to HDL is a strong risk predictor (Lindenstrom et al., 1994; Gaziano et al., 1997). 
Lipoprotein lipase is a key enzyme in triglyceride hydrolysis, and its gene is located 
on chromosome 8p22, with 9 exons and 29.6 kb. Genetic variants can lead to lipid disorders 
and increase atherosclerosis risk. The HindIII polymorphism is a base transition of thymine 
(T) to guanine (G) at position +495 in intron 8, which abolishes the restriction site for the 
enzyme HindIII and the H- allele has less affinity for a transcription regulator factor of the 
LPL gene. The S447X polymorphism is characterized by the substitution of cytosine (C) by 
guanine (G) at position 1595 in exon 9, resulting in a premature stop codon, which removes 
the last two amino acids of the protein. The X allele is associated with higher LPL activity 
(Hata et al., 1990; Kobayashi et al., 1992; Chen et al., 2008). 
In the literature, X allele frequency ranges from 10 to 20%, while the frequency of 
genotype XX is 1%. H- allele frequency ranges from 21 to 30%, while the frequency of geno-
type HH is 7 to 10%. Previous studies in Brazilians showed the X allele in 12 to 17.8% and 
H- allele in 28.4 to 34.8% (Almeida et al., 2007; Gigek et al., 2007; Sepetiba et al., 2007). 
The exact mechanism of action of these polymorphisms is however controversial, 
but the X allele and H- allele are associated with protection against myocardial infarction and 
ischemic stroke. It is probable that benefits are through lipid metabolism, although some re-
search shows an effect independent of blood lipid levels (Morrison et al., 2002). 
We studied elderly men to determine if these polymorphisms are associated with HDL 
and triglyceride levels in this group. 
MATERIAL AND METHODS
Population
We included a total of 87 men of 65 years of age or more from the Division of Ge-
riatrics and Gerontology of UNIFESP (Federal University of São Paulo); 48 had had acute 
coronary syndrome or ischemic stroke [cardiovascular (CV) group], and 39 had had no previ-
ous cardiovascular event, its equivalents or diabetes (control group) (Sposito et al., 2007). All 
patients with acute disease, uncontrolled diabetes or systemic disease were excluded. Subjects 
were considered to be positive for cardiovascular disease when they self-reported previous 
myocardial infarction or angina pectoris with Intensive Care Unit admission or ischemic stroke 
and taking specific medication prescribed by physicians. The clinical information obtained per-
tained to personal and family medical history and lifestyle. Physicians performed a physical ex-
amination with weight, height and blood pressure measurements. Blood samples were collected 
after 12 h fasting for laboratory procedures. The Research Ethics Committee approved this 
study, and all participants signed informed consent form, according to the Helsinki Declaration. 
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Laboratory exams and DNA extraction
Lipid and lipid fraction measurements were performed using routine enzymatic tests. 
We calculated risk ratio I = total cholesterol to HDL, desirable, equal to or less than 4.9; risk 
ratio II = LDL to HDL, desirable, equal to or less than 2.4, and risk ratio III = triglyceride to 
HDL, desirable, equal to or less than 3.8 (Anonymous, 2001). Blood was collected in tubes 
containing 0.1% EDTA, and genomic DNA was isolated using a modification of the procedure 
reported by Lahiri and Nurnberger Jr. (1991). 
Polymorphism detection
Primer sequences, polymerase chain reaction (PCR) conditions and restriction enzyme 
digestions were as follows (oligonucleotides were synthesized by Promicro, São Paulo, Bra-
zil). For the HindIII polymorphism, the forward primer was 5’-GATGTCTACCTGGATAAT 
CAAAG-3, and the reverse primer was 5’-CTTCAGCTAGACATTGCTAGTGT’-3. PCR was 
carried out in a 50-mL reaction volume containing 100 ng genomic DNA, 0.4 mM of each 
primer, 0.2 mM dNTPs (Invitrogen, Carlsbad, CA, USA), 2 mM MgCl
2
 in 10% PCR buffer and 
1 U DNA polymerase (DNA directed; Invitrogen, São Paulo, Brazil). PCR involved an initial 
5-min denaturation at 96ºC, 40 cycles of denaturation at 94ºC for 1 min, annealing at 57ºC for 
1 min and extension at 72ºC for 1 min, with a final extension at 72ºC for 7 min. Aliquots of 8 
mL of the PCR products were digested with 2.5 U HindIII (MBI Fermentas, Vilnius, Lithuania) 
at 37ºC for 4 h. The common H+ allele has one restriction site and produces two fragments of 
210 and 140 bp. For the S447X polymorphism, the forward primer was 5’-TACACTAGCAAT 
GTCTAGGTGA-3’, and the reverse primer was 5’-TCAGCTTTAGCCCAGAATGC-3’. The 
PCR volume was as described for HindIII, with initial denaturation for 5 min at 94ºC, 40 cycles 
of denaturation for 1 min at 94oC, annealing for 1 min at 60ºC and extension for 30 s at 72ºC, 
and a final extension for 7 min at 72ºC. Samples were digested with 2.5 U MnlI (MBI Fer-
mentas) for 4 h at 37ºC. The polymorphic X allele has two restriction sites and produces three 
fragments of 285, 250 and 203 bp. Restriction fragment length polymorphism (RFLP) products 
were analyzed on 3% agarose gel and stained with ethidium bromide. 
Statistical analysis
SAS 9.1 (Statistical Analysis System, Cary, NC, USA) was used to perform the chi-
square test, analysis of variance, logistic regression analysis, and the Student t-test. Genotype 
and allele frequencies were calculated by allele counting (Emery, 1986). Genotype distribu-
tion was investigated in relation to Hardy-Weinberg equilibrium using the “Genepop on the 
web” website (Garnier-Gere and Dillmann, 1992). 
RESULTS 
The mean age was 76 years (range: 65-90 years) and 77% were Caucasian. In cardio-
vascular cases, 52% (25/48) had suffered ischemic stroke, 42% (20/48) acute coronary syn-
drome and 6% (3/48) both. The prevalence of hypertension, low HDL levels and cardiovas-
cular family cases was higher in the CV group when compared to control subjects (Table 1).
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In Table 2, we present the genotype frequency in control and CV groups, and there 
were no differences between them. The S447X and the HindIII polymorphisms were in link-
age disequilibrium. The H- allele and X allele frequencies in the CV group were 25.53 and 
22.34% and 30.77 and 20.51% in the control group, respectively. There were no differences in 
allele frequencies between the groups.
Characteristics Controls (N = 39) CV cases (N = 48) P
Age (years)  75.84 ± 5.83 77.33 ± 6.77     0.2819
Hypertension  18 (46.15%)  34 (70.83%)       0.0342*
SBP (mmHg)  136.22 ± 16.64 144.48 ± 24.07     0.0626
DBP (mmHg)  78.97 ± 9.97 84.41 ± 9.74       0.0121*
BMI (kg/m2)  26.78 ± 3.84 26.12 ± 3.88     0.4387
Cholesterol (mM)    4.70 ± 0.93   4.69 ± 0.98     0.9361
LDL-C (mM)   2.72 ± 0.86   2.88 ± 0.92     0.4116
HDL- C (mM)   1.29 ± 0.29   1.16 ± 0.23        0.0196*
Triglycerides (mM)   1.64 ± 0.98   1.47 ± 0.82     0.4068
Risk ratio I    3.84 ± 1.22   4.18 ± 1.17     0.1864
Risk ratio II    2.20 ± 0.93   2.58 ± 0.99     0.0759
Risk ratio III  2.62 (2.12 to 3.26) 2.69 (2.31 to 3.14)     0.8480
Family CHD    5 (12.82%) 17 (35.42%)       0.0278*
Current smoker   5 (12.82%)   6 (12.50%) 1.00
Previous smoker 18 (46.15%) 27 (56.25%) 0.47
Regular exercise 22 (56.41%) 26 (54.17%) 1.00
Table 1. Baseline characteristics of the controls and cardiovascular (CV) cases.
Data are reported as means ± SD and number with percent in parentheses, except for Risk ratio III. *P < 0.05. SBP 
= systolic blood pressure; DBP = diastolic blood pressure; BMI = body mass index; Risk ratio I = total cholesterol/
HDL-C; Risk ratio II = LDL-C/HDL-C; Risk ratio III = triglyceride/HDL-C (geometric mean 95%CI); family CHD 
= family history of premature cardiovascular disease.
Genotype Controls  CV cases  Total  P
H+H+ 19 (48.72%) 26 (55.32%) 45 (52.33%) 0.7621
H+H- 16 (41.03%) 18 (38.30%) 34 (39.53%) 
H-H-   4 (10.26%) 3 (6.38%) 7 (8.14%) 
SS 23 (58.97%) 26 (55.32%) 49 (56.98%) 0.8282
SX 16 (41.03%) 21 (44.68%) 37 (43.02%) 
XX 0 0 0
Table 2. Comparison of the genotype frequencies of S447X and HindIII polymorphisms of the LPL gene in 
controls and cardiovascular (CV) cases.
Data are reported as number with percent in parentheses. 1Fisher exact test; 2Pearson chi-square test.
The influence of these polymorphisms on lipid blood levels was determined by com-
paring the presence and absence of H- and X alleles in all subjects. The presence of X allele 
was associated with lower triglyceride/HDL ratio (risk ratio III = 2.30, 95%CI = 1.92 to 2.76 
vs 3.02, 95%CI = 2.53 to 3.57 - for X allele absent, P = 0.03), as shown in Table 3. The HindIII 
alleles were not associated with risk ratio and lipid levels. Medications to treat lipid disorders 
were distributed equally between X and H- allele carriers and non-carriers (data not shown; P 
= 0.78 and P = 0.53, respectively). In Table 4, the H-X haplotype was associated with lower 
triglyceride levels compared to the H+S haplotype (1.22 vs 1.58 mM, geometric mean 95%CI, 
respectively) and lower triglyceride/HDL ratio (risk ratio III = 2.29, 95%CI = 1.82 to 2.86 vs 
3.26, 95%CI = 2.58 to 4.11). There were no differences in the medications used to treat lipid 
disorders between any polymorphism haplotype carriers (data not shown; P = 0.81). 
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Lipid profile  HindIII (N = 86)    S447X (N = 86)
 H- allele absent H- allele present P X allele present X allele absent P
 (N = 45) (N = 41)  (N = 37) (N = 49)
Cholesterol (mM)  4.62 ± 0.94 4.76 ± 0.99 0.49 4.76 ± 0.90 4.65 ± 1.01 0.61
LDL-C (mM) 2.72 ± 0.81 2.89 ± 0.98 0.38 2.88 ± 0.88 2.76 ± 0.89 0.55
HDL-C (mM) 1.19 ± 0.29 1.24 ± 0.24 0.49 1.27 ± 0.27 1.17 ± 0.26 0.09
Triglycerides (mM) 1.69 ± 1.12 1.39 ± 0.54 0.12 1.35 ± 0.56 1.71 ± 1.07 0.06
Risk ratio I  4.08 ± 1.29 3.98 ± 1.12 0.69 3.92 ± 1.19 4.13 ± 1.21 0.43
Risk ratio II  2.39 ± 0.99 2.43 ± 0.98 0.85 2.39 ± 1.01 2.43 ± 0.96 0.84
Risk ratio III  2.90 (2.37 to 3.52) 2.42 (2.05 to 2.83) 0.15 2.30 (1.92 to 2.76) 3.02 (2.53 to 3.57)   0.03*
Non-HDL-C (mM)  3.43 ± 0.95 3.52 ± 1.00 0.85 3.49 ± 0.95 3.48 ± 1.00 0.95
Table 3. Blood lipid levels according to the HindIII and the S447X polymorphisms of the LPL gene in all the sample.
Data are reported as means ± SD, except for Risk ratio III. *P < 0.05. Risk ratio I = total cholesterol/HDL-C; 
Risk ratio II = LDL-C/HDL-C; Risk ratio III = triglyceride/HDL-C (geometric mean 95%CI); non-HDL-C = total 
cholesterol-HDL-C.
Lipid profile H+S (CV risk) H-X (CV protection) P
 (N = 32) (N = 24)
Cholesterol (mM)  4.65 ± 1.06 4.84 ± 1.04 0.5092
LDL-C** (mM) 2.82 ± 2.34 to 3.41 2.85 ± 2.47 to 3.28 0.9429
HDL-C (mM) 1.14 ± 0.25 1.24 ± 0.23 0.1299
Triglycerides** (mM) 1.58 ± 1.32 to 1.90 1.22 ± 1.03 to 1.45   0.0449*
Risk ratio I  4.27 ± 1.31 4.04 ± 1.22 0.5354
Risk ratio II    2.52 ± 12.46 2.52 ± 1.08 0.9512
Risk ratio III  3.26 ± 2.58 to 4.11 2.29 ± 1.82 to 2.86   0.0353*
Non-HDL-C (mM)  3.51 ± 1.06 3.60 ± 1.08 0.7609
Table 4. Blood lipid levels in the H+S and H-X haplotypes of the LPL gene carriers in all the sample.
Data are repoted as means ± SD. *P < 0.05; **Geometric mean 95%CI. Risk ratio I = total cholesterol/HDL-C; 
Risk ratio II = LDL-C/HDL-C; Risk ratio III = triglyceride/HDL-C; non-HDL-C = total cholesterol-HDL-C. CV 
= cardiovascular disease.
There were no differences between haplotype carriers in other lipids and their clinical-
ly recommended lipid levels (Table 5). Considering the clinical endpoint, there was a tendency 
(P = 0.06) towards less family history of premature cardiovascular disease in H-X haplotype 
carriers (Table 6).
Desirable lipid parameters H+S (CV risk) H-X (CV protection) P
 (N = 32) (N = 24)
LDL-C less than 2.56 mM      15 (48.39%) 10 (41.67%) 0.6196
HDL-C greater than or equal to 1.03 mM      21 (61.63%) 20 (83.33%) 0.1386
Triglycerides less than 1.69 mM      19 (59.38%) 17 (70.83%) 0.3758
Risk ratio I less than or equal to 4.9  24 (75%) 17 (70.83%) 0.7275
Risk ratio II less than or equal to 2.4       17 (54.84%) 14 (58.33%) 0.7950
Risk ratio III less than or equal to 3.8      10 (31.25%)   4 (16.67%) 0.2123
Non-HDL-C less than 3.33 mM 16 (50%) 11 (45.83%) 0.7575
Table 5. Proportion of H+S and H-X haplotypes of the LPL gene carriers with clinically recommended blood 
lipid levels and risk ratios of cardiovascular (CV) disease in all the sample.
Data are reported as number with percent in parentheses. Risk ratio I = total cholesterol/HDL-C; Risk ratio II = 
LDL-C/HDL-C; Risk ratio III = triglyceride/HDL-C; non-HDL-C = total cholesterol-HDL-C.
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DISCUSSION
In the present study, the X allele was associated with a lower triglyceride/HDL-C ratio, 
which points to benefits in triglyceride metabolism. The H- allele was not associated with blood 
lipids. Nevertheless, H-X haplotypes were associated with lower triglyceride levels and lower 
triglyceride/HDL-C ratio when compared to the H+S haplotype. The frequency of H- allele was 
27.9% and of X allele 21.5%, with no differences between CV and control groups. 
Medications to treat lipid disorders could reduce triglyceride levels and elevate HDL 
levels and, as a consequence, could be a factor that reduced our findings of the association 
between these polymorphism and lipid profile in these subjects. However, we expect that these 
medications influenced all groups in the same proportion because they were equally distributed 
between all groups - common and uncommon allele carriers and CV and control groups. 
In our sample, 77% were considered to be Caucasian because of parental geographic 
origin and skin color. In the methods, we decided to ask about parental origin plus personal 
skin color due to allele frequencies being lower in black people. It seems that there are no 
differences between Hispanics and white non-Hispanics (Razzaghi et al., 2000). Hence, we 
understand that this sample is comparable to Caucasians in other studies. 
Considering that lipoproteins may be influenced by way of life and genetic poly-
morphism, the influence of these polymorphisms on lipoprotein levels could be minimized 
by these elderly men’s lifestyle. Current smoking prevalence was 12% and we observed a 
70% reduction compared to previous smoking. More than half of the subjects were practicing 
physical exercise. 
There is little information about impact of age on expression of these polymorphisms, 
and it is possible that there is a difference between elderly and younger adults. The frequency 
of LPL HindIII polymorphism was 50% in Russians older than 90 years of age. In elderly 
Brazilians with age range from 66 to 97 years (mean of 79 years), the H- allele was found in 
34.8% and the X allele in 17.6%. Allele H+ was associated with coronary disease in both stud-
ies (Malygina et al., 2001; Gigek et al., 2007). In our study, allele H- frequency was slightly 
lower (27.9%), possibly due to the lower mean age (76 years) or the sample size. It is known 
that HDL level shows an age-X polymorphism interaction, with association of X allele after 10 
years of age and a reduction of effect after 30 years (Chen et al., 2001; Hallman et al., 2001; 
Thu et al., 2006). Thus, interaction between age, polymorphisms and lipoprotein requires fur-
ther research. Some studies have also shown that the impact of these polymorphisms on fe-
males is not significant (Ahn et al., 1993; Mattu et al., 1994; Humphries et al., 1998; Nicklas 
et al., 2000; McGladdery et al., 2001; Van Bockxmeer et al., 2001). 
Other studies have evaluated these polymorphisms in Brazilian subjects younger than 
the subjects in our study. A case-control study with 12 normolipidemic subjects with X allele 
History of cardiovascular disease H+S (CV risk) H-X (CV protection) P
 (N = 32) (N = 24)
Personal (case group) 18 (56.25%) 13 (54.17%) 0.8767
Family 11 (34.38%)   3 (12.50%) 0.0614
Table 6. History of cardiovascular (CV) disease in H+S and H-X haplotypes of the LPL gene carriers in all the sample.
Data are reported as number with percent in parentheses.
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(mean age: 36 years) and in 13 control subjects without this allele (mean age: 33 years) has 
shown no differences in chylomicron metabolism evaluated by doubly labeled chylomicron-
like emulsion injected intravenously (Almeida et al., 2003). In another case-control study, X 
allele was associated with lower triglyceride levels and cardiovascular protection in CAD pa-
tients of less than 55 years and 150 controls (Almeida et al., 2007). The S447 and HindIII LPL 
polymorphisms were assessed in 309 non-diabetic patients with angiographic CAD (mean 
age: 59.1 years) and in 197 controls (mean age: 55.3 years) in a southern Brazilian population 
of European descent. H- allele was associated with lower triglycerides and higher HDL-C 
and the X allele was associated with lower triglyceride levels in males. Carriers of H-S and 
H-X haplotypes showed lower triglycerides and increased HDL-C levels when compared to 
the H+S haplotype, and the H- haplotype was associated with a significant protective effect 
against CAD in the male subjects (Almeida et al., 2003). 
In conclusion, our results in elderly men show that carriers of X allele have a better 
triglyceride/HDL-C ratio and that H-X haplotype carriers have lower triglyceride levels and a 
better triglyceride/HDL-C ratio. H- allele was not associated with blood lipids or cardiovascu-
lar events. Knowledge of polymorphism in this population is a path to a better understanding 
of genetic influence in triglyceride metabolism and cardiovascular risk in the elderly. 
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